During the first three years of the national prevention program the Ministry of Health, with the support of Merck, will offer GARDASIL to appropriate girls 12 to 15 years of age.
While QIAGEN‘s DNA-based molecular diagnostic HPV tests – the digene HC2 HPV DNA Test and the careHPV Test – will be offered to women between the ages of 35 and 45.
Merck will provide more than two million doses of GARDASIL to the Government of Rwanda at no cost, while QIAGEN will provide 250,000 HPV screening tests at no cost along with all necessary equipment and training to successfully perform the tests.
Thereafter, the government of Rwanda will continue routine vaccination of appropriate 12 year old girls, and Merck will provide GARDASIL at a discounted access price that is made available for national vaccination programs in GAVI-eligible countries.
Similarly, QIAGEN will make its HPV tests accessible under a tiered-market pricing structure designed to enable developing countries to establish and maintain the use of HPV testing within national cervical cancer screening and treatment programs.
